Metastatic non-small cell lung cancer with EGFR exon 19 deletion

Metastatic non-small cell lung cancer with an EGFR exon 19 deletion is an advanced, stage IV malignancy arising from the respiratory epithelium that has disseminated beyond the thorax to distant sites such as the brain, bones, liver, or adrenal glands

Metastatic non-small cell lung cancer with an EGFR exon 19 deletion is an advanced, stage IV malignancy arising from the respiratory epithelium that has disseminated beyond the thorax to distant sites such as the brain, bones, liver, or adrenal glands Clinically, tumors harboring this common activating alteration exhibit marked oncogenic addiction and high therapeutic sensitivity to EGFR tyrosine kinase inhibitors

Metastatic non-small cell lung cancer with an EGFR exon 19 deletion is an advanced, stage IV malignancy arising from the respiratory epithelium that has disseminated beyond the thorax to distant sites such as the brain, bones, liver, or adrenal glands This disease subtype primarily occurs within lung adenocarcinomas and is classically enriched in women, individuals of East Asian ancestry, and patients with light or no history of tobacco use

This disease subtype primarily occurs within lung adenocarcinomas and is classically enriched in women, individuals of East Asian ancestry, and patients with light or no history of tobacco use

This disease subtype primarily occurs within lung adenocarcinomas and is classically enriched in women, individuals of East Asian ancestry, and patients with light or no history of tobacco use

Pathophysiologically, in-frame deletions within exon 19 of the epidermal growth factor receptor gene alter the intracellular tyrosine kinase domain, leading to ligand-independent, constitutive receptor activation that drives malignant cell proliferation and survival

Pathophysiologically, in-frame deletions within exon 19 of the epidermal growth factor receptor gene alter the intracellular tyrosine kinase domain, leading to ligand-independent, constitutive receptor activation that drives malignant cell proliferation and survival Clinically, tumors harboring this common activating alteration exhibit marked oncogenic addiction and high therapeutic sensitivity to EGFR tyrosine kinase inhibitors

Clinically, tumors harboring this common activating alteration exhibit marked oncogenic addiction and high therapeutic sensitivity to EGFR tyrosine kinase inhibitors